ARV-393
Pipeline Category
Pharmaceutical
Short Description / Indication
ARV-393 is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) BCL6 degrader developed by Arvinas for the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL).
Areas of Focus
Oncology
Licensees
| Company Name | Company Website URL |
|---|---|
| Arvinas | https://www.arvinas.com/ |
Pharmaceutical Status